Sep 29, 2016
Bayer AG and Evotec AG enter a multi-target research partnership agreement Bayer and Evotec have agreed to develop novel treatments for chronic kidney disease in diabetic patients. According to the agreement, Bayer will have all the rights to select clinical candidates and Evotec’s Cure Nephron target pipeline. It w...
Read More...
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Newsletter/Whitepaper